Diagnostic relevance of Humanin, GAS5 and miR-21/miR-103 in prostate disease risk stratification
Authors:
Open Access
- 6 August 2025
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 25 (1) , 1-13
Abstract
This study aimed to evaluate the diagnostic significance of circulating mitochondrial-derived peptides, Humanin and MOTS-c, the long non-coding RNA GAS5, and exosomal microRNAs miR-21 and miR-103 in stratifying prostate diseases, including benign prostatic hyperplasia (BPH), precancerous lesions (PL), and prostate cancer (PCa). These biomarkers were selected based on their established roles in cellular stress responses, apoptosis regulation, inflammation, and tumor progression. A cohort of 375 male patients suspected of prostate cancer were enrolled. Plasma and exosomal levels of Humanin, MOTS-c, GAS5, miR-21, and miR-103 were measured. Diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis, principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), and decision tree models. Results showed significant downregulation of Humanin and GAS5 in both PL and PCa compared to BPH, supporting their role in early disease transition. Exosomal miR-21 and miR-103 were significantly upregulated in PCa, with miR-21 exhibiting outstanding discriminative power between BPH and PL (AUC = 1.000) and between PL and PCa (AUC = 0.9932). MOTS-c, a mitochondrial-derived peptide, displayed elevated levels in PL compared to BPH, suggesting its involvement in early malignant transformation. A plasma-only diagnostic model combining Humanin, GAS5, and MOTS-c reached 95% cross-validated classification accuracy across clinical groups. Combination of circulating Humanin, MOTS-c, GAS5, and exosomal miRNAs provides a promising non-invasive biomarker panel for risk stratification in prostate diseases. This integrated molecular approach may enhance diagnostic precision and guide personalized clinical decision-making in prostate cancer management. Graphical abstractKeywords
Funding Information
- Consiglio Nazionale delle Ricerche
This publication has 72 references indexed in Scilit:
- Prostate cancer: Advances in diagnostic research2025
- Dysregulation of GAS5–miRNA-Mediated Signaling Pathways in Cancer Pathobiology: A Comprehensive Exploration of Pathways Influenced by this AxisBiochemical Genetics, 2024
- A Review on Mitochondrial Derived Peptide Humanin and Small Humanin-Like Peptides and Their Therapeutic StrategiesInternational Journal of Peptide Research and Therapeutics, 2023
- Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer ResearchClinical Genitourinary Cancer, 2023
- Unravelling the role of long non-coding RNAs in prostate carcinomaAdvances in Cancer Biology - Metastasis, 2022
- Racial differences in circulating mitochondria‐derived peptides may contribute to prostate cancer health disparitiesThe Prostate, 2022
- Decision tree-based diagnosis of coronary artery disease: CART modelComputer Methods and Programs in Biomedicine, 2020
- MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to BedsideTargeted Oncology, 2020
- Long noncoding RNA GAS5 suppresses the migration and invasion of hepatocellular carcinoma cells via miR-21Tumor Biology, 2015
- Principal component analysisChemometrics and Intelligent Laboratory Systems, 1987